Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Aberrant DNA Methylation and Epigenetic Inactivation of hMSH2 Decrease Overall Survival of Acute Lymphoblastic Leukemia Patients via Modulating Cell Cycle and Apoptosis

  • Wang, Cai-Xia (Department of Internal Medicine, Guangzhou First People's Hospital, Guangzhou Medical University) ;
  • Wang, Xiang (School of Public Health, Guangzhou Medical University) ;
  • Liu, Hai-Bai (School of Public Health, Guangzhou Medical University) ;
  • Zhou, Zhi-Heng (School of Public Health, Guangzhou Medical University)
  • Published : 2014.01.15
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: Altered regulation of many transcription factors has been shown to play important roles in the development of leukemia. hMSH2 can modulate the activity of some important transcription factors and is known to be a regulator of hematopoietic differentiation. Herein, we investigated epigenetic regulation of hMSH2 and its influence on cell growth and overall survival of acute lymphoblastic leukemia (ALL) patients. Methods: hMSH2 promoter methylation status was assessed by COBRA and pyrosequencing in 60 ALL patients and 30 healthy volunteers. mRNA and protein expression levels of hMSH2, PCNA, CyclinD1, Bcl-2 and Bax were determined by real time PCR and Western blotting, respectively. The influence of hMSH2 on cell proliferation and survival was assessed in transient and stable expression systems. Results: mRNA and protein expression of hMSH2 and Bcl-2 was decreased, and that of PCNA, CyclinD1 and Bax was increased in ALL patients as compared to healthy volunteers (P<0.05). hMSH2 was inactivated in ALL patients through promoter hypermethylation. Furthermore, hMSH2 hypermethylation was found in relapsed ALL patients (85.7% of all cases). The median survival of patients with hMSH2 methylation was shorter than that of patients without hMSH2 methylation (log-rank test, P=0.0035). Over-expression of hMSH2 in cell lines resulted in a significant reduction in growth and induction of apoptosis. Conclusions: This study suggests that aberrant DNA methylation and epigenetic inactivation of hMSH2 play an important role in the development of ALL through altering cell growth and survival.

Keywords

References

  1. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP (1998). Alterations in DNA methylation: A fundamental aspect of neoplasia. Adv Cancer Res, 72, 141-96.
  2. Blyth K, Slater N, Hanlon L, et al (2009). Runx1promotes B-cell survival and lymphoma development. Blood cells Mol Dis, 43, 12-9. https://doi.org/10.1016/j.bcmd.2009.01.013
  3. Brooks KR, To K, Joshi MBM, et al (2003). Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection. Ann Thorac Surg, 76, 187-93. https://doi.org/10.1016/S0003-4975(03)00131-0
  4. Caixia W, Ping M, Qinghua D, et al (2009). CpG island methylation of hMLH1 and hMSH2 gene and their expressions in acute leukemia patients. Chin J Public Health, 7, 870-2.
  5. Calvisi, D F, Ladu S, Gorden A, et al (2007). Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest, 117, 2713-22. https://doi.org/10.1172/JCI31457
  6. Cameron ER, Neil JC (2004). The Runx genes: lineage-specific oncogenes and tumor suppressors. Oncogene, 23, 4308-14. https://doi.org/10.1038/sj.onc.1207130
  7. Choi JH, Park SH, Park J, et al (2007). Site-specific methylation of CpG nucleotides in the hTERT promoter region can control the expression of hTERT during malignant progression of colorectal carcinoma. Biochem Biophys Res Commun, 361, 615-20. https://doi.org/10.1016/j.bbrc.2007.07.051
  8. Costello JF, Plass C (2001). Methylation matters. J Med Genet, 38, 285-303. https://doi.org/10.1136/jmg.38.5.285
  9. Deguchi M, Shiina H, Igawa M, et al (2003). DNA mismatch repair genes in renal cell carcinoma. J Urol, 169, 2365-71. https://doi.org/10.1097/01.ju.0000065668.19267.b4
  10. Fishel R (2001). The selection for mismatch repair defects in hereditary nonpolyposis colorectal cancer: Revising the mutator hypothesis. Cancer Res, 61, 7369-74.
  11. Fiumicino S, Martinelli S, Colussi C, et al(2000). Sensitivity to DNA crosslinking chemotherapeutic agents inmismatch repair-defective cells in vitro and in xenografts. Int J Cancer, 85, 590-6. https://doi.org/10.1002/(SICI)1097-0215(20000215)85:4<590::AID-IJC23>3.0.CO;2-O
  12. Gaynon PS (2005). Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol, 131, 579-87. https://doi.org/10.1111/j.1365-2141.2005.05773.x
  13. Hewish M, Lord CJ, Martin SA, et al (2010). Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol, 7, 197-208. https://doi.org/10.1038/nrclinonc.2010.18
  14. Kuang SQ, Tong WG, Yang H, et al (2008). Genomewide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia, 22, 1529-38. https://doi.org/10.1038/leu.2008.130
  15. KyungHwa L, JiShin L, JongHee N, et al (2011). Promoter methylation status of hMLH1, hMSH2, and MGMT genes in colorectal cancer associated with adenoma-carcinoma sequence. Langenbecks Arch Surg, 396, 1017-26. https://doi.org/10.1007/s00423-011-0812-9
  16. Ligtenberg MJ, Kuiper RP, Chan TL, et al (2009). Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3-exons of TACSTD1. Nat Genet, 41, 112-7. https://doi.org/10.1038/ng.283
  17. Loo TW, Clarke DM (2005). Recentprogress in understanding themechanism of P-glycoprotein-mediated drug efflux. J Membrn Bio, 206, 173-85. https://doi.org/10.1007/s00232-005-0792-1
  18. Marsischky GT, Filosi N, Kane MF, et al (1996). Redundancy of Saccharomyces cerevisiae MSH3 and MSH6 in MSH2-dependent mismatch repair. Genes Dev, 10, 407-20. https://doi.org/10.1101/gad.10.4.407
  19. Meyers M, Wagner MW, Hwang HS, et al (2001). Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidinemediated cell death and cell cycle responses. Cancer Res, 61, 5193-201.
  20. Meyers M, Wagner MW, Mazurek A, et al (2005). DNA mismatch repair-dependent response to fluoropyrimidinegenerated damage. J Biol Chem, 280, 5516-26. https://doi.org/10.1074/jbc.M412105200
  21. Mrozek K, Heerema NA, Bloomfield CD (2004). Cytogenetics in acute leukemia. Blood Rev, 18, 115-36. https://doi.org/10.1016/S0268-960X(03)00040-7
  22. O'Neil J, Look AT (2007). Mechanisms of transcription factor deregulation in lymphoid cell transformation. Oncogene, 26, 6838-49. https://doi.org/10.1038/sj.onc.1210766
  23. Plasschaert SL, Kamps WA, Vellenga E, et al (2004). Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation? Cancer Treat Rev, 30, 37-51. https://doi.org/10.1016/S0305-7372(03)00140-3
  24. Pogribny P, James SJ (2002). De novo methylation of the p16INK4A gene in early preneoplastic liver and tumors induced by folate/methyl deficiency in rats. Cancer Lett, 187, 69-75. https://doi.org/10.1016/S0304-3835(02)00408-1
  25. Pui CH, Carroll WL, Meshinchi S, et al (2011). Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol, 29, 551-65. https://doi.org/10.1200/JCO.2010.30.7405
  26. Pui CH, Relling MV, Downing JR (2004). Acute lymphoblastic leukemia. N Engl J Med, 350, 1535-48. https://doi.org/10.1056/NEJMra023001
  27. Ribic CM, Sargent DJ, Moore MJ, et al (2003). Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med, 349, 247-57. https://doi.org/10.1056/NEJMoa022289
  28. Shaoqing K, Hao B, Zhihong F, et al (2010). Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia. Blood, 115, 2412-9. https://doi.org/10.1182/blood-2009-05-222208
  29. Shimizu K, Onishi M, Sugata E, et al (2007). Disturbance of DNA methylation patterns in the early phase of hepatocarcinogenesis induced by a cholinedeficient l-amino acid-defined diet in rats. Cancer Sci, 98, 1318-22. https://doi.org/10.1111/j.1349-7006.2007.00564.x
  30. Slany RK (2005). When epigenetics kills: MLL fusion proteins in leukemia. Hematol Oncol, 23, 1-9. https://doi.org/10.1002/hon.739
  31. Takeshi N, Jennifer R, Matthias K, et al (2010). Somatic Hypermethylation of MSH2 Is a Frequent Event in Lynch Syndrome Colorectal Cancers. Cancer Res, 70, 3098-108. https://doi.org/10.1158/0008-5472.CAN-09-3290
  32. Ward RL, Cheong K, Ku SL, et al (2003). Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol, 21, 3729-36. https://doi.org/10.1200/JCO.2003.03.123
  33. Xinarianos G, LiloglouT, PrimeW, et al (2000). hMLH1and hMSH2 expression correlates with allelic imbalance on chromosome 3p in non-small cell lung carcinomas. Cancer Res, 60, 4216-21.
  34. Yongzhong H, Fengqin G, Qinhong, et al (2007). Mechanisms of signal transduction: Bcl2 impedes DNA mismatch repair by directly regulating the hMSH2-hMSH6 heterodimeric complex. J Biol Chem, 282, 9279-87. https://doi.org/10.1074/jbc.M608523200
  35. Youn CK, Cho H, Kim S, et al (2005). Bcl-2 expression suppresses mismatch repair activity through inhibition of E2F transcriptional activity. Nat Cell Biol, 7, 137-47. https://doi.org/10.1038/ncb1215
  36. Yu X, Hong S, Faustman EM (2008). Cadmium-induced activation of stress signaling pathways, disruption of ubiquitin-dependent protein degradation and apoptosis in primary rat Sertoli cell-gonocyte cocultures. Toxicol Sci, 104, 385-96.
  37. Zelent A, Greaves M, Enver T (2004). Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia. Oncogene, 23, 4275-83. https://doi.org/10.1038/sj.onc.1207672
  38. Zhiheng Z, Yixiong L, Caixia W (2012). Analysis of aberrant methylation in DNA repair genes during malignant transformation of human bronchial epithelial cells induced by cadmium. Toxicol Sci., 125, 412-7. https://doi.org/10.1093/toxsci/kfr320

Cited by

  1. Allogeneic Hemopietic Stem Cell Transplants for the Treatment of B Cell Acute Lymphocytic Leukemia vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6127
  2. A seven-gene CpG-island methylation panel predicts breast cancer progression vol.15, pp.1, 2015, https://doi.org/10.1186/s12885-015-1412-9
  3. CD26: A Prognostic Marker of Acute Lymphoblastic Leukemia in Children in the Post Remission Induction Phase vol.16, pp.12, 2015, https://doi.org/10.7314/APJCP.2015.16.12.5059